Feasibility of different meningioma delineation approaches on [18F]SiTATE PET/CT imaging
Somatostatin receptor (SSTR)-targeted PET is valuable for meningioma imaging due to high SSTR expression. [18F]SiTATE, a novel tracer, is not only promising for imaging neuroendocrine tumors but also for meningiomas. Standardized delineation methods on [18F]SiTATE PET are lacking. This study correlates CT-based volumes with PET-based delineation approaches to identify a threshold for standardized [18F]SiTATE PET volume assessment. Patients with well-delineated, extraosseous meningioma on CT (≥ 1mL) who underwent [18F]SiTATE PET/CT were included. Volumes were assessed on contrast-enhanced CT and correlated with PET-based delineation approaches: (I) fixed SUV threshold, (II) isocontour thresholding relative to SUVmax (SUV%), and thresholds relative to (III) bone marrow (SUVBM), (IV) parotid gland (SUVparotis) and (V) pituitary gland (SUVsella). 19 meningiomas in 17 PET/CT scans (16 patients) were included. A fixed SUV of 4.0 (r = 0.783, p < 0.001) showed good correlation with CT volumes without skewed distribution on Bland-Altman-Plot analysis. Using isocontour-based thresholds, 45% SUVmax (r = 0.496, p = 0.031) showed the highest concordance. Best reference-based approaches were achieved by 150% SUVBM (r = 0.859, p < 0.001), 250% SUVparotis (r = 0.460, p = 0.047) and 70% SUVsella (r = 0.819, p < 0.001). However, background-based approaches showed a trend towards overestimation of PET-volumes in larger meningiomas as assessed on Bland-Altman-Plot analyses. Uptake intensities of reference tissues (SUVBM, SUVparotis and SUVsella) were not inter-correlated (p > 0.05 each). A fixed SUV threshold of 4.0 showed strong agreement with CT-based volumes in well-delineated, extraosseous meningiomas which offers a simple, clinically applicable method without technical requirements. Reference tissue-based methods showed similar correlations but tended to overestimate volumes in larger lesions.
Authors
- Lena M. Unterrainer
- Peter Bartenstein
- Claus Belka (ORCID: https://orcid.org/0000-0002-1287-7825)
- Christian Schichor (ORCID: https://orcid.org/0000-0001-6684-3578)
- Michael Winkelmann (ORCID: https://orcid.org/0000-0003-4655-7341)
- Carmen Wängler (ORCID: https://orcid.org/0000-0003-1161-8669)
- Ralf Schirrmacher (ORCID: https://orcid.org/0000-0002-7098-3036)
- Adrien Holzgreve (ORCID: https://orcid.org/0000-0002-9566-8438)
- Alexander Nitschmann (ORCID: https://orcid.org/0009-0000-8620-2305)
- Marcus Unterrainer (ORCID: https://orcid.org/0000-0002-8238-1198)
- Wolfgang G. Kunz (ORCID: https://orcid.org/0000-0002-5021-1952)
- Klaus Jurkschat (ORCID: https://orcid.org/0000-0001-9930-858X)
- Niklas Thon (ORCID: https://orcid.org/0000-0003-0011-5281)
- Björn Wängler (ORCID: https://orcid.org/0000-0003-3877-5576)
- Simon Lindner (ORCID: https://orcid.org/0009-0007-4379-4436)
- Sophie C. Kunte (ORCID: https://orcid.org/0009-0003-3175-952X)
Institutions
- University of Alberta (CA)
- TU Dortmund University (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- LMU Klinikum (DE)
- Ihre-Radiologen (DE)
- Molecular Theranostics (United States) (US)
- University Medical Centre Mannheim (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1007/s12672-025-04079-6
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft